Cohen Syndrome is a rare autosomal recessive disorder caused by biallelic mutations in the VPS13B gene. It is characterized by multiple clinical features, including acquired microcephaly, developmental delay, intellectual disability, neutropenia, and retinal degeneration. Recent research has focused on understanding the cellular functions of the VPS13B protein to uncover the pathological mechanisms underlying the syndrome.
VPS13B is part of the bridge-like lipid transport (BLTP) protein family, which includes proteins that act as lipid transport proteins at organellar membrane contact sites. Unlike other members of this family, VPS13B is predominantly localized at the Golgi apparatus. It is essential for the maintenance of organelle architecture, and its depletion leads to Golgi fragmentation, a prominent cellular defect observed in Cohen Syndrome models.
Researchers have identified several potential binding partners for VPS13B, including RAB6, a GTPase involved in Golgi traffic regulation, and SNARE proteins like Syntaxin 6. These interactions suggest that VPS13B may play a crucial role in vesicular trafficking and lipid mobilization within the Golgi complex. The disruption of these processes due to VPS13B mutations is believed to contribute to the diverse clinical manifestations of Cohen Syndrome.
Understanding the precise molecular function of VPS13B is a critical step toward developing targeted therapies for Cohen Syndrome. Future studies will likely focus on elucidating the specific lipid species transported by VPS13B and how its dysfunction leads to the neurological and systemic symptoms observed in patients.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.